Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viemed HealthcareVMD +1.43%93 Beneish M-Score is -3.20 as of Jul. 17, 2026. GuruFocus rates VMD with a GF Score™ of 93/100 and a GF Value™ of $10.94 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 763 Medical Devices & Instruments companies, Viemed Healthcare ranks better than 83.36% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -3.2 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for Viemed Healthcare's Beneish M-Score or its related term are showing as below:
VMD'
s Beneish M-Score Range Over the Past 10 Years
Min: -3.3 Med: -2.9 Max: 233.46
Current: -3.2
During the past 10 years, the highest Beneish M-Score of Viemed Healthcare was 233.46. The lowest was -3.30. And the median was -2.90.
Viemed Healthcare Beneish M-Score Related Terms
Viemed Healthcare Beneish M-Score Historical Data
* Premium members only.
The historical data trend for Viemed Healthcare's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Viemed Healthcare's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viemed Healthcare Beneish M-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Viemed Healthcare's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Viemed Healthcare's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Viemed Healthcare for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 0.9455
+
0.528 * 1.0197
+
0.404 * 1.3684
+
0.892 * 1.231
+
0.115 * 0.8617
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 0.9515
+
4.679 * -0.211577
-
0.327 * 1.1261
=
-3.20
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(25.696 / (25.696 + 83.962))
/
(29.621 / (29.621 + 79.308))
=
0.234329
/
0.271929
=
0.8617
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(14.891 - -0.485
-
57.133)
/
197.361
=
-0.211577
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Viemed Healthcare has a M-score of -3.20 suggests that the company is unlikely to be a manipulator.
Viemed Healthcare (VMD) has a Beneish M-Score of -3.20 as of Jul. 17, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Viemed Healthcare and its competitors. According to the industry distribution chart, Viemed Healthcare ranks #127 out of 763 companies in the Medical Devices & Instruments industry, placing it in the top 16.6%.
Is Viemed Healthcare's Beneish M-Score too high?
Viemed Healthcare's current Beneish M-Score is -3.20. Based on the distribution chart, Viemed Healthcare ranks #127 out of 763 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Viemed Healthcare has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viemed Healthcare's Beneish M-Score compare to DCTH and VREX?
According to the Medical Devices & Instruments industry distribution chart, Viemed Healthcare ranks #127 out of 763 companies for Beneish M-Score. This places Viemed Healthcare in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Viemed Healthcare and its competitors. Viemed Healthcare's current Beneish M-Score is -3.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viemed Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Viemed Healthcare (VMD) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.94, compared to a current price of $12.11 — trading 10.7% above its estimated fair value. The current Beneish M-Score is -3.20. Viemed Healthcare's overall GF Score™ is 93/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Viemed Healthcare (VMD), the current Beneish M-Score is -3.20 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viemed Healthcare (VMD) Overvalued in 2026?
Based on GuruFocus' analysis, Viemed Healthcare stock appears to be overvalued.
The current stock price of $12.11 is trading 10.7% above its estimated GF Value™ of $10.94.
GuruFocus considers Viemed Healthcare to be Modestly Overvalued.
Key valuation signals for VMD:
Beneish M-Score: -3.20
GF Value™: $10.94 vs. price of $12.11 (10.7% above fair value)
No single metric tells the full story. See the VMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.
93GF Score
Get the complete analysis for VMD
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VMD has been successfully added to your 
